There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ligand Pharma (LGND) and Arvinas Holding Company (ARVN) with bullish sentiments.
Ligand Pharma (LGND)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma yesterday and set a price target of $229.00. The company’s shares closed last Monday at $102.15.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 24.7% and a 54.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Ligand Pharma is a Strong Buy with an average price target of $183.75, implying an 80.3% upside from current levels. In a report issued on October 6, Barclays also initiated coverage with a Buy rating on the stock with a $156.00 price target.
See today’s analyst top recommended stocks >>
Arvinas Holding Company (ARVN)
In a report released yesterday, Andrew Fein from H.C. Wainwright maintained a Buy rating on Arvinas Holding Company, with a price target of $60.00. The company’s shares closed last Monday at $24.88.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.0% and a 45.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
Arvinas Holding Company has an analyst consensus of Moderate Buy, with a price target consensus of $61.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
